case_images: PMC11792013_01
case_images: Disease progression in the skin: (a) diffuse erythroderma covering >90% of BSA and presence of desquamation in November 2021 and (b) worsening itching and desquamation in December 2021.. BSA, body surface area.
case_images: 10.1177_20406207251317165-fig1.jpg
case_images: PMC11792013_01_10.1177_20406207251317165-fig1.jpg
case_images: fig1-20406207251317165
case_images: By November 2021, the patient experienced continued disease progression, with erythroderma covering >90% of the patient's BSA and desquamation (Figure 1(a)). By the end of December, erythema worsened, progressing to erythroderma in subsequent weeks with itching and desquamation on the back and thighs (Figure 1(b)), and serum LDH was slightly elevated (260 U/L).
case_images: Persistence of bullous lesions with bubble-like appearance following discontinuation of PUVA during combination mogamulizumab treatment: (a) patient's back and (b) patient's arm.. PUVA, psoralen plus ultraviolet light A.
case_images: 10.1177_20406207251317165-fig2.jpg
case_images: PMC11792013_02_10.1177_20406207251317165-fig2.jpg
case_images: fig2-20406207251317165
case_images: Presence of diffuse erythema on the trunk only, and residual effects of bullous lesions during ongoing mogamulizumab monotherapy (April 2023).
case_images: 10.1177_20406207251317165-fig3.jpg
case_images: PMC11792013_01_10.1177_20406207251317165-fig3.jpg
case_images: fig3-20406207251317165
case_images: Mogamulizumab monotherapy is currently ongoing (August 2024), maintaining the clinical stability of the skin disease (erythema affecting 20%-30% of BSA; Figure 3) and reducing lymphadenopathies (with a few pericentimetric laterocervical lymph nodes remaining).
case_images: PMC11792013_02
case_images: Persistence of bullous lesions with bubble-like appearance following discontinuation of PUVA during combination mogamulizumab treatment: (a) patient's back and (b) patient's arm.. PUVA, psoralen plus ultraviolet light A.
case_images: 10.1177_20406207251317165-fig2.jpg
case_images: PMC11792013_02_10.1177_20406207251317165-fig2.jpg
case_images: fig2-20406207251317165